Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer

被引：0
|
作者：
Kang, S. [1 ]
Lee, S. H. [2 ]
Lee, H. J. [3 ]
Jeong, H. [4 ]
Jeong, J-H. [2 ]
Kim, J. E. [2 ]
Ahn, J-H. [2 ]
Jung, K. H. [2 ]
Kim, H. H. [5 ]
Lee, S. [6 ]
Lee, J.
Kim, S-B. [2 ]
机构：
[1] Chungnam Natl Univ Hosp, Hemato Oncol, Daejeon, South Korea
[2] Univ Ulsan, Asan Med Ctr, Coll Med, Dept Oncol, Seoul, South Korea
[3] Univ Ulsan, Pathol, Asan Med Ctr, Coll Med, Seoul, South Korea
[4] Univ Ulsan, Dept Internal Med, Asan Med Ctr, Coll Med, Seoul, South Korea
[5] Univ Ulsan, Dept Radiol, Asan Med Ctr, Seoul, South Korea
[6] Univ Ulsan, Surg, Asan Med Ctr, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.501
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
305P
引用
收藏
页码：S305 / S305
页数：1
相关论文
共 50 条
  • [31] Improving HER2 testing reproducibility in HER2-low breast cancer
    Sajjadi, Elham
    Venetis, Konstantinos
    Ivanova, Mariia
    Fusco, Nicola
    CANCER DRUG RESISTANCE, 2022, 5 (04) : 882 - 888
  • [32] Her2 low status and response to neoadjuvant chemotherapy in Her2 negative early breast cancer
    Mattos, Bruna RaphaeliSilva
    Cesca, Marcelle Goldner
    Leite, Luciana de Moura
    Tavares, Monique Celeste
    Silva, Sinara Figueiredo
    Pirolli, Rafaela
    Fogassa, Camilla AlbinaZanco
    Silva, Erick Figueiredo
    Rocha, Francisca Giselle
    Loose, Simone Klug
    Campos, Fernando AugustoBatista
    Sanches, Solange Moraes
    de Lima, Vladmir ClaudioCordeiro
    Ponde, Noam Falbel
    CANCER RESEARCH, 2021, 81 (04)
  • [33] Prognosis difference between HER2-low and HER2-zero breast cancer patients: a systematic review and meta-analysis
    Li, Chengxin
    Yuan, Qianqian
    Deng, Tong
    Xu, Gaoran
    Hou, Jinxuan
    Zheng, Lewei
    Wu, Gaosong
    BREAST CANCER, 2023, 30 (06) : 965 - 975
  • [34] Prognosis difference between HER2-low and HER2-zero breast cancer patients: a systematic review and meta-analysis
    Chengxin Li
    Qianqian Yuan
    Tong Deng
    Gaoran Xu
    Jinxuan Hou
    Lewei Zheng
    Gaosong Wu
    Breast Cancer, 2023, 30 : 965 - 975
  • [35] Prognostic implications of HER2 gain in patients with HR+/ HER2-breast cancer (BC) and TNBC after neoadjuvant chemotherapy (NAC)
    Ferraro, E.
    Minmin, S. Chew
    Nemirovsky, D.
    Chen, Y.
    Barrio, A. V.
    Modi, S.
    Seidman, A.
    Wen, H.
    Brogi, E.
    Robson, M.
    Dang, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S301 - S301
  • [36] Development and validation of machine learning models for predicting HER2-zero and HER2-low breast cancers
    Huang, Xu
    Wu, Lei
    Liu, Yu
    Xu, Zeyan
    Liu, Chunling
    Liu, Zaiyi
    Liang, Changhong
    BRITISH JOURNAL OF RADIOLOGY, 2024, 97 (1161):
  • [37] Re: Pathologic complete responses, long-term outcomes, and recurrence patterns in HER2-low vs. HER2-zero breast cancer after neoadjuvant chemotherapy: Several issues about HER2 expression and neoadjuvant chemotherapy in breast cancer (vol 180, pg 184, 2023)
    Yang, Fan
    Liu, Guanmo
    Mao, Feng
    Zheng, Yong-Chang
    EUROPEAN JOURNAL OF CANCER, 2024, 200
  • [38] HER2-low vs HER2-zero metastatic breast carcinoma: A clinical and genomic descriptive analysis
    Sanchez Bayona, R.
    Luna, A. M.
    Tolosa, P.
    Sanchez De Torre, A.
    Castelo, A.
    Marin, M.
    Garcia, C.
    Boni, V.
    Bernal Hertfelder, E.
    Vega, E.
    Rojas, B.
    Bratos, R.
    Martinez, M.
    Diaz Bermejo, A. J.
    Lema, L.
    Manso, L.
    Ciruelos, E. M.
    ANNALS OF ONCOLOGY, 2021, 32 : S29 - S30
  • [39] Predictive factors for outcome in HER2-low breast cancer patients after neoadjuvant chemotherapy
    Shao, Yingbo
    Guan, Huijuan
    Luo, Zhifen
    Yu, Yang
    He, Yaning
    Chen, Qi
    Liu, Chaojun
    Zhu, Fangyuan
    Liu, Hui
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [40] Preliminary study on DCE-MRI radiomics analysis for differentiation of HER2-low and HER2-zero breast cancer
    Yin, Liang
    Zhang, Yun
    Wei, Xi
    Shaibu, Zakari
    Xiang, Lingling
    Wu, Ting
    Zhang, Qing
    Qin, Rong
    Shan, Xiuhong
    FRONTIERS IN ONCOLOGY, 2024, 14
12345